STOX1 and central nervous system cancer: Further multivariate Cox regression analyses revealed that STOX1 downregulation predicted shorter overall survival of glioma patients (Tables 3 and 4) (HR: 0.731, 95% CI: 0.542–0.987, and P = 0.041 in CGGA and HR: 0.719, 95% CI: 0.469–1.104, and P = 0.132 in TCGA).